Botulinum toxin type A in the treatment of Raynaud's phenomenon
Authors:
- 14 August 2020
- journal article
- research article
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 33 (6) , e14182
Abstract
Raynaud phenomenon is a vasospastic disorder clinically characterized by cold or stress‐induced discoloration of the skin, pain and ulcers of the fingers or toes. Although this phenomenon might be self‐limiting, there is a subgroup of patients requiring a therapeutic approach. The majority of patients do well on conservative measures, however, there is also a subgroup requiring systemic treatment. The efficacy of these systemic treatments is currently not thoroughly investigated. Furthermore, no uniform guidelines exist regarding the choice for a treatment option. In the past several years, several reports have shown the benefits of botulinum toxin for the treatment of Raynaud's phenomenon. In this case series, we report our experience with botulinum toxin type A in the treatment of Raynaud's phenomenon.Keywords
This publication has 14 references indexed in Scilit:
- Botulinum Toxin Off-Label Use in Dermatology: A ReviewSkin Appendage Disorders, 2017
- The Role of Botulinum Toxin A in the Treatment of Raynaud PhenomenonAnnals of Plastic Surgery, 2016
- Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series studyThe Journal of Dermatology, 2015
- Treatment of Raynaud’s phenomenon with botulinum toxin type ANeurological Sciences, 2015
- The pathogenesis, diagnosis and treatment of Raynaud phenomenonNature Reviews Rheumatology, 2012
- Botox Therapy for Ischemic DigitsPlastic and Reconstructive Surgery, 2009
- Botulinum Toxin Type A: A Treatment Option for Digital Ischemia in Patients With Raynaud's PhenomenonThe Journal of Hand Surgery, 2009
- Management of Vasospastic Disorders with Botulinum Toxin APlastic and Reconstructive Surgery, 2007
- Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot studyEuropean Journal of Clinical Investigation, 2004
- Subcutaneous administration of botulinum toxin A reduces formalin-induced painPain, 2004